MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Net Debt 2011-2026 | ZOM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.83 M | -5.21 M | -10.2 M | -25.7 M | -194 M | 466 K | -511 K | -1.94 M | -3.45 M | -82.1 K | -143 K | -207 K | -79.7 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 466 K | -194 M | -19 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 19.21 | -3.37 % | $ 123 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.0 | 2.63 % | $ 108 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.53 | 0.8 % | $ 1.33 B | Canada |
 |
Aurora Cannabis
ACB
|
285 M | $ 3.44 | 2.69 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.63 | -1.56 % | $ 2.7 M |  China |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
338 M | $ 8.23 | -1.79 % | $ 421 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.17 | 2.26 % | $ 44.6 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 5.35 | -4.12 % | $ 1.95 B | Canada |
 |
Harrow Health
HROW
|
178 M | $ 35.31 | -0.34 % | $ 1.3 B | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
94.8 M | $ 4.03 | -6.5 % | $ 260 M | USA |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 2.24 | -3.03 % | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
317 M | $ 22.7 | -0.39 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
3.1 B | $ 10.85 | -1.36 % | $ 1.5 B | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 6.99 | -1.55 % | $ 276 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-730 K | $ 0.96 | 2.54 % | $ 34.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.37 | -2.47 % | $ 2.94 M | USA |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 7.49 | 1.49 % | $ 655 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 13.44 | -1.39 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
-521 K | $ 0.73 | 2.37 % | $ 3.15 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 0.89 | -0.05 % | $ 44.4 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
TherapeuticsMD
TXMD
|
-1.39 M | $ 2.0 | - | $ 23.1 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.36 | 2.26 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
14.4 M | $ 6.55 | 6.68 % | $ 4.05 B | Canada |